Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

BACKGROUND: Although it is accepted that metastatic colorectal cancers (mCRCs) that carry activating mutations in KRAS are unresponsive to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, a significant fraction of KRAS wild-type (wt) mCRCs are also unresponsive to anti-EGFR therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, J B, Dutta, D, Watson, D, Maddala, T, Munneke, B M, Shak, S, Rowinsky, E K, Xu, L-A, Harbison, C T, Clark, E A, Mauro, D J, Khambata-Ford, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049558/
https://www.ncbi.nlm.nih.gov/pubmed/21206494
http://dx.doi.org/10.1038/sj.bjc.6606054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049558/
https://www.ncbi.nlm.nih.gov/pubmed/21206494
http://dx.doi.org/10.1038/sj.bjc.6606054

Ejemplares similares